Chronic HCV infection affects around 3% of the world population and is the leading cause of cirrhosis, liver cancer and liver transplantation. Pegylated interferon/ribavirin (pegIFN/RBV) therapy is the treatment of choice for HCV infection. SRV is dependent on virus genotype as well as on patients‘ factors including genetic polymorphisms.
IL28B RealFast™ Assay is the accurate way to test the therapeutic response of antiviral therapy in Hepatitis C Virus (HCV) infected patients. It helps to predict the success of antiviral therapy and sustained virologic response (SVR) in HCV infected patients. The TT>∆G variant in the IFNL4 gene is the strongest known host factor for predicting HCV clearance. Genotyping of TT>∆G helps to predict the outcome of pegIFN/RBV therapy independent of a patient‘s ethnicity. IL28B pcr IL28B pcr
RealFast™ Assays technology
The ViennaLab RealFast™ Assays are based on real-time PCR and hydrolysis probes, also commonly called TaqMan® probes. The sequence-specific oligonucleotide probes carry a fluorescent reporter dye at the 5´-end and a quencher dye at the 3´-end. While the probe is intact, the quencher is close enough to the reporter to suppress the fluorescent signal of the 5´-fluorophore. During the combined annealing/extension phase of PCR, the probe is cleaved by the 5´ to 3´ exonuclease activity of Taq DNA polymerase, thereby separating the fluorophore from the quencher dye. This process results in detectable fluorescence, which is proportional to the amount of accumulated PCR product.
|IL28B RealFast™ Assay||7-200||100 reactions||detects HCV clearance|
|IL28B RealFast™ Assay||7-203||32 reactions||detects HCV clearance|